Výsledky vyhledávání

Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non–Small-Cell Lung Cancer

Autor: Jared Weiss, Anastasia Ivanova, Mark A. Socinski, Juneko E. Grilley-Olson, Joseph Shan, Carrie B. Lee, Thomas E. Stinchcombe, Dominic T. Moore, Liza C. Villaruz

Publikováno v: Clinical Lung Cancer. 19:e481-e487

Introduction Bavituximab is an immunomodulatory chimeric monoclonal antibody that inhibits phosphatidylserine signaling, which promotes innate and adaptive immune responses. In this phase Ib trial we evaluated the safety, tolerability, and preliminar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b96356a308142569f94a19f025ddf3b2
https://doi.org/10.1016/j.cllc.2018.03.008

Zobrazit plný text záznamu

BMT CTN 1803: Trial to Investigate If Haploidentical Natural Killer Cells (CSTD002) Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Autor: Elizabeth F. Krakow, Nelli Bejanyan, Leo Luznik, Steven M. Devine, Richard E. Champlin, Sumithira Vasu, Joseph Shan, Elizabeth O. Hexner, Brittany K. Ragon, Emma Barrett, Brent R. Logan

Publikováno v: Biology of Blood and Marrow Transplantation. 26:S371-S372

Background and Rationale Relapse remains the leading cause of treatment failure for 30–50% of patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic blood or marrow transplantation (BMT). Safet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea1107ad62550f78335dc5e9162969b9
https://doi.org/10.1016/j.bbmt.2019.12.174

Zobrazit plný text záznamu

Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non–Small-Cell Lung Cancer

Autor: Joseph Shan, David E. Gerber, Kerstin B. Menander, David Giorgadze, David R. Spigel, Mikhail Shtivelband, Chandra P. Belani, Olga V. Ponomarova

Publikováno v: Clinical Lung Cancer. 17:169-176

Background Bavituximab is a phosphatidylserine-targeting antibody with a selective tumor, vascular-directed immune response. In this phase II trial the efficacy and safety of bavituximab combined with docetaxel for previously treated, advanced nonsqu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::749a7f11aa55668d52d49389870fd9cb
https://doi.org/10.1016/j.cllc.2016.02.003

Zobrazit plný text záznamu

A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer

Autor: Alison Stopeck, Denise J. Roe, Maria Iannone, Robert B. Livingston, Marilyn T. Marron, Pavani Chalasani, Kathryn Clarke, Joseph Shan

Publikováno v: Cancer Medicine

Bavituximab is a chimeric monoclonal antibody that targets phosphatidylserine (PS). PS is externalized on cells in the tumor microenvironment when exposed to hypoxia and/or other physiological stressors. On attaching to PS, bavituximab is thought to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d426f483f74d388a13a1a49e2888869
https://doi.org/10.1002/cam4.447

Zobrazit plný text záznamu

Plný text ve formátu HTML

Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer

Autor: Lokanatha Dasappa, Raghunadharao Digumarti, Attili V. Suresh, David E. Gerber, Joseph Shan, P.P. Bapsy, Gouri Shankar Bhattacharyya

Publikováno v: Lung Cancer. 86:231-236

Objective Bavituximab is a phosphatidylserine (PS)-targeting monoclonal antibody with immune-modulating and tumor-specific vascular targeting properties. Preclinical studies have shown activity against numerous solid tumors and at least an additive e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc96993962feaddefa1055e6021b4d2f
https://doi.org/10.1016/j.lungcan.2014.08.010

Zobrazit plný text záznamu

Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors

Autor: Philip E. Thorpe, Alison Stopeck, David E. Gerber, Lucas Wong, Nuhad K. Ibrahim, Lee S. Rosen, Joseph Shan

Publikováno v: Clinical Cancer Research. 17:6888-6896

Purpose: Bavituximab is a chimeric immunoglobulin G1 phosphatidylserine-targeting monoclonal antibody that triggers vascular disruption and enhances antitumor immune response. This phase I study assessed the safety and pharmacokinetics of bavituximab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88b0109cdfd51fbcd5a9f112001211c0
https://doi.org/10.1158/1078-0432.ccr-11-1074

Zobrazit plný text záznamu

Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma

Autor: Sadnu Budha, Rachel Giese, Aditi Gupta, Olivier De Henau, Roberta Zappasodi, Luis Felipe Campesato, Christopher Barker, Joseph Shan, Jedd D Wolchok, Taha Merghoub

Publikováno v: The Journal of Immunology. 200:122.10-122.10

Phosphatidylserine (PS) is a phospholipid that is exposed on surface of apoptotic cells, some tumor cells and tumor endothelium. It has been shown to promote immunosuppressive signals in the tumor microenvironment. Radiation therapy (RT) is an effect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a52064f927f1728a1a2d47c0ea7733b9
https://doi.org/10.4049/jimmunol.200.supp.122.10

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání